U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 21 results

Status:
US Approved Rx (2007)
First approved in 2007

Class (Stereo):
CHEMICAL (ACHIRAL)



Nilotinib (AMN107, trade name Tasigna) is a kinase inhibitor indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in adult patients resistant to or intolerant to prior ...
Status:
US Approved Rx (2019)
First approved in 2001

Class (Stereo):
CHEMICAL (ACHIRAL)



Imatinib (GLEEVEC®) is a tyrosine kinase inhibitor and antineoplastic agent that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukaemia (CML). It...
CGP-74588 (Norimatinib, N-Desmethyl Imatinib) is a metabolite of Imatinib, a tyrosine kinase inhibitor, displaying specificity for BCR-ABL. CGP-74588 is pharmacologically active, and shows a similar potency and selectivity profile as the parent drug
GNF-2 is an inhibitor of Abl kinase that exhibits anticancer chemotherapeutic, anti-resorptive, and anti-osteoporotic activities. GNF-2 causes a dose-dependent growth inhibition of the Bcr-abl–positive cell lines with IC50 values of 273 nM (K562) and...
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ACHIRAL)



Radotinib (Supect) was developed and approved in Korea as a second-line Chronic Myeloid Leukemia treatment. The drug supresses cancer cells proliferation by inhibitiing BCR-ABL1 kinase which is a driver of Philadelphia chromosome-positive (Ph+) leuke...
Status:
US Approved Rx (2007)
First approved in 2007

Class (Stereo):
CHEMICAL (ACHIRAL)



Nilotinib (AMN107, trade name Tasigna) is a kinase inhibitor indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in adult patients resistant to or intolerant to prior ...
Status:
US Approved Rx (2007)
First approved in 2007

Class (Stereo):
CHEMICAL (ACHIRAL)



Nilotinib (AMN107, trade name Tasigna) is a kinase inhibitor indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in adult patients resistant to or intolerant to prior ...
Status:
US Approved Rx (2007)
First approved in 2007

Class (Stereo):
CHEMICAL (ACHIRAL)



Nilotinib (AMN107, trade name Tasigna) is a kinase inhibitor indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in adult patients resistant to or intolerant to prior ...
Status:
US Approved Rx (2007)
First approved in 2007

Class (Stereo):
CHEMICAL (ACHIRAL)



Nilotinib (AMN107, trade name Tasigna) is a kinase inhibitor indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in adult patients resistant to or intolerant to prior ...